Clinical Study

Debio 1143-106- A Smac Mimetic In Combination With Nivolumab In Patients Failing Prior Pd-1/Pd-L1 Treatment

Posted Date: Dec 30, 2019

  • Investigator: Shuchi Gulati
  • Specialties: Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Oncology, Ovarian Cancer, Pancreatic Cancer
  • Type of Study: Drug

The purpose of this study is to determine overall safety/tolerability and PK by optimizing doses of Debio 1143 when combined with the standard dose of nivolumab, as well as treatment compliance in patients with advanced solid malignancies who failed prior systemic standard treatments.

Criteria:

To Be Eligible: >18 Years Of Age, Confirmed Advanced/ Unresectable Or Metastatic Solid Tumor Dx, At Least 1 Prior Line Of Chemo, No Liver Cirrhosis, No Known Uncontrolled Cardiac History, Medical Diagnosis, Or Active Infection Interfering With Study Results Or Pt Safety

Keywords:

Cancer, Phase 1

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.